Bergen, Norway, 4 November 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
significant unmet medical needs, is pleased to announce a poster presentation at
the 63[rd] Annual American Society of Hematology (ASH) Meeting, taking place 11
-14[th] December 2021 in Atlanta, GA.

Prof Sonja Loges will provide an update from the Company's Phase II study
(BGBC003) of bemcentinib in combination with low dose cytarabine (LDAC) in
older, relapsed and refractory AML patients unfit for intensive chemotherapy.

The data to be presented suggest that bemcentinib in combination with LDAC is
well tolerated and offers promising survival benefit to relapsed AML patients.
Translational research has further identified immune-based activity associated
with response to treatment, suggesting that bemcentinib elicits activation of
the two major adaptive immune cell populations responsible for anti-AML immune
effect.

Abstracts have been announced online and details of the presentation are below.

Title: Bemcentinib (Oral AXL Inhibitor) in combination with Low-dose Cytarabine
Is Well Tolerated and Efficacious in Older Relapsed AML Patients. Updates from
the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results
indicating Bemcentinib elicits anti-AML immune responses.

Date: Monday, December 13, 2021

Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding
Transplantation and Cellular Immunotherapies: Poster III

Time, Location: 6.00 - 8.00 PM Eastern, Georgia World Congress Center, Hall B5

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com


International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer, leukaemia
and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing a potential companion diagnostic test to identify patient populations
most likely to benefit from AXL inhibition: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.